A peptide inhibitor called RI-AG03 targets major aggregation “hot spots” of tau proteins, believed to be a key driver of ...

The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized ...

“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the ...

Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in ...

An international team of researchers has made a significant breakthrough in Alzheimer's drug development with the ...

An international team of researchers led by Lancaster University has made a promising breakthrough in the development of ...

An international team of researchers have made a promising breakthrough in the development of drugs to treat Alzheimer's Disease. For the first time, scientists have developed a drug that works on ...

Now, an international team led by Lancaster University in the UK says it has developed a drug called RI-AG03 that targets and blocks the two “hot spots” where tau clumping tends to occur.

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in the journal Alzheimer's & Dementia, a team of researchers report the ...

AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models.

In people with Alzheimer's disease, they clump together, starve brain cells of nutrients and slow down signals in the organ ...

AG03, developed by researchers at the University of Southampton, targets two critical regions of the tau protein linked to ...